JP2005535285A - 分子肝毒性モデリング - Google Patents

分子肝毒性モデリング Download PDF

Info

Publication number
JP2005535285A
JP2005535285A JP2003564220A JP2003564220A JP2005535285A JP 2005535285 A JP2005535285 A JP 2005535285A JP 2003564220 A JP2003564220 A JP 2003564220A JP 2003564220 A JP2003564220 A JP 2003564220A JP 2005535285 A JP2005535285 A JP 2005535285A
Authority
JP
Japan
Prior art keywords
genes
gene
liver
expression level
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003564220A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005535285A5 (https=
Inventor
ドナ メンドリック，
マーク ポーター，
コリー ジョンソン，
ブランドン ヒッグス，
アーサー カストル，
ミカエル エラショフ，
Original Assignee
ジーン ロジック インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジーン ロジック インコーポレイテッド filed Critical ジーン ロジック インコーポレイテッド
Publication of JP2005535285A publication Critical patent/JP2005535285A/ja
Publication of JP2005535285A5 publication Critical patent/JP2005535285A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2003564220A 2002-01-31 2003-01-31 分子肝毒性モデリング Pending JP2005535285A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6008702A 2002-01-31 2002-01-31
US36405502P 2002-03-15 2002-03-15
US36404502P 2002-03-15 2002-03-15
US43664302P 2002-12-30 2002-12-30
PCT/US2003/003194 WO2003064624A2 (en) 2002-01-31 2003-01-31 Molecular hepatotoxicology modeling

Publications (2)

Publication Number Publication Date
JP2005535285A true JP2005535285A (ja) 2005-11-24
JP2005535285A5 JP2005535285A5 (https=) 2006-03-16

Family

ID=27670970

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003564220A Pending JP2005535285A (ja) 2002-01-31 2003-01-31 分子肝毒性モデリング

Country Status (6)

Country Link
US (1) US20070027634A1 (https=)
EP (1) EP1476747A4 (https=)
JP (1) JP2005535285A (https=)
AU (1) AU2003214981A1 (https=)
CA (1) CA2471661A1 (https=)
WO (1) WO2003064624A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013031375A (ja) * 2011-07-29 2013-02-14 Medichrome:Kk 遺伝子発現変動解析による化学物質の毒性評価方法
JP2016104032A (ja) * 2016-02-23 2016-06-09 株式会社メディクローム 化学物質の生体毒性の評価方法
WO2025192110A1 (ja) * 2024-03-11 2025-09-18 国立大学法人東北大学 ベクターおよびその使用、並びに医薬組成物

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7447594B2 (en) 2001-07-10 2008-11-04 Ocimum Biosolutions, Inc. Molecular cardiotoxicology modeling
US20050071088A1 (en) * 2001-08-13 2005-03-31 Landfield Philip W Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
JP2007501617A (ja) * 2003-08-07 2007-02-01 ジーン ロジック インコーポレイテッド 初代ラット肝細胞毒性モデリング
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
US8131473B1 (en) * 2004-05-20 2012-03-06 Metabolon, Inc. Data analysis methods for locating entities of interest within large, multivariable datasets
KR100565698B1 (ko) * 2004-12-29 2006-03-28 디지탈 지노믹스(주) 급성골수성백혈병(aml), b-세포형 급성임파구성백혈병(b-all), t 세포형 급성임파구성백혈병(t-all) 진단용 마커
JP5202296B2 (ja) * 2005-04-01 2013-06-05 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド 肝臓傷害のバイオマーカー
US8048638B2 (en) * 2005-04-01 2011-11-01 University Of Florida Research Foundation, Inc. Biomarkers of liver injury
US10957217B2 (en) 2006-08-25 2021-03-23 Ronald A. Weitzman Population-sample regression in the estimation of population proportions
US11151895B2 (en) * 2006-08-25 2021-10-19 Ronald Weitzman Population-sample regression in the estimation of population proportions
ES2665245T3 (es) 2008-08-11 2018-04-25 Banyan Biomarkers, Inc. Proceso de detección de biomarcador y ensayo de estado neurológico
US12601749B2 (en) 2008-08-11 2026-04-14 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
EP2264454A1 (en) * 2009-06-11 2010-12-22 Universiteit Maastricht Method for screening compounds for preventing the adverse effects of reactive oxygen species on eukaryotic cells
WO2012141674A2 (en) 2010-01-26 2012-10-18 Banyan Biomarkers, Inc. Compositions and methods relating to argininosuccinate synthetase
EP3077823B1 (en) * 2013-12-05 2019-09-04 The Broad Institute, Inc. Compositions and methods for identifying and treating cachexia or pre-cachexia
EP3389715A4 (en) 2015-12-14 2019-06-12 David K. Thomas COMPOSITIONS AND METHODS FOR TREATING CARDIAL DYSFUNCTION
WO2018081649A1 (en) 2016-10-28 2018-05-03 Banyan Biomarkers, Inc. Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0680517T4 (da) * 1993-01-21 2005-05-02 Harvard College Fremgangsmåde og diagnostiske sæt til bestemmelse af en forbindelses toksicitet under anvendelse afstress-promotorer fra pattedyr
US5858659A (en) * 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US6228589B1 (en) * 1996-10-11 2001-05-08 Lynx Therapeutics, Inc. Measurement of gene expression profiles in toxicity determination
CA2269669A1 (en) * 1996-11-04 1998-05-14 3-Dimensional Pharmaceuticals, Inc. System, method and computer program product for identifying chemical compounds having desired properties
US6165709A (en) * 1997-02-28 2000-12-26 Fred Hutchinson Cancer Research Center Methods for drug target screening
US6153421A (en) * 1997-07-18 2000-11-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloned genomes of infectious hepatitis C viruses and uses thereof
WO1999010536A1 (en) * 1997-08-22 1999-03-04 Yale University A process to study changes in gene expression in granulocytic cells
CA2310621A1 (en) * 1997-11-20 1999-06-03 Smithkline Beecham Corporation Methods for identifying the toxic/pathologic effect of environmental stimuli on gene transcription
JP2002505852A (ja) * 1998-01-26 2002-02-26 シェーリング アクティエンゲゼルシャフト 化合物をスクリーニングするための遺伝子発現方法
US6403778B1 (en) * 1998-05-04 2002-06-11 Incyte Genomics, Inc. Toxicological response markers
US6218122B1 (en) * 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6132969A (en) * 1998-06-19 2000-10-17 Rosetta Inpharmatics, Inc. Methods for testing biological network models
US6203987B1 (en) * 1998-10-27 2001-03-20 Rosetta Inpharmatics, Inc. Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns
EP1137809A1 (en) * 1998-12-09 2001-10-04 Vistagen, Inc. Toxicity typing using embryoid bodies
EP1147224A1 (en) * 1999-02-05 2001-10-24 WRAIR (Walter Reed Army Institute of Research) Method of diagnosing of exposure to toxic agents by measuring distinct pattern in the levels of expression of specific genes
US6372431B1 (en) * 1999-11-19 2002-04-16 Incyte Genomics, Inc. Mammalian toxicological response markers
US20010049139A1 (en) * 2000-03-23 2001-12-06 Eric Lagasse Hepatic regeneration from hematopoietic stem cells
KR100865664B1 (ko) * 2000-06-14 2008-10-29 비스타겐 인코포레이티드 간 줄기 세포를 사용하는 독성 타이핑
WO2002006537A2 (en) * 2000-07-13 2002-01-24 Curagen Corporation Methods of identifying renal protective factors
EP1364049A2 (en) * 2000-07-31 2003-11-26 Gene Logic, Inc. Molecular toxicology modeling
US20030154032A1 (en) * 2000-12-15 2003-08-14 Pittman Debra D. Methods and compositions for diagnosing and treating rheumatoid arthritis
US7993907B2 (en) * 2001-05-08 2011-08-09 Mowycal Lending, Llc Biochips and method of screening using drug induced gene and protein expression profiling
EP1397144A4 (en) * 2001-05-15 2005-02-16 Psychogenics Inc SYSTEMS AND METHODS FOR MONITORING BEHAVIOR INFORMATION

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013031375A (ja) * 2011-07-29 2013-02-14 Medichrome:Kk 遺伝子発現変動解析による化学物質の毒性評価方法
JP2016104032A (ja) * 2016-02-23 2016-06-09 株式会社メディクローム 化学物質の生体毒性の評価方法
WO2025192110A1 (ja) * 2024-03-11 2025-09-18 国立大学法人東北大学 ベクターおよびその使用、並びに医薬組成物

Also Published As

Publication number Publication date
CA2471661A1 (en) 2003-08-07
US20070027634A1 (en) 2007-02-01
EP1476747A2 (en) 2004-11-17
WO2003064624A2 (en) 2003-08-07
EP1476747A4 (en) 2008-06-11
WO2003064624A3 (en) 2003-12-11
AU2003214981A1 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
JP2005535285A (ja) 分子肝毒性モデリング
Yeh et al. Effect of contaminants of emerging concern on liver mitochondrial function in Chinook salmon
Canesi et al. Environmental effects of BPA: focus on aquatic species
Rosen et al. Gene profiling in the livers of wild-type and PPARα-null mice exposed to perfluorooctanoic acid
AU2025204996A1 (en) Method for designing rna binding protein utilizing ppr motif, and use thereof
AU2025201794A1 (en) Detecting breast cancer
Brausch et al. Human pharmaceuticals in the aquatic environment: a review of recent toxicological studies and considerations for toxicity testing
Depiereux et al. Intersex occurrence in rainbow trout (Oncorhynchus mykiss) male fry chronically exposed to ethynylestradiol
Linhart et al. Comparison of sperm velocity, motility and fertilizing ability between firstly and secondly activated spermatozoa of common carp (Cyprinus carpio)
Uren Webster et al. The herbicide linuron inhibits cholesterol biosynthesis and induces cellular stress responses in brown trout
Anderson et al. Acute maneb exposure significantly alters both glycolysis and mitochondrial function in neuroblastoma cells
Kurogi et al. The use of zebrafish as a model system for investigating the role of the SULTs in the metabolism of endogenous compounds and xenobiotics
Montgomery et al. Exposure to 17α‐ethinylestradiol decreases motility and ATP in sperm of male fighting fish Betta splendens
AU2024220214A1 (en) Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1
Miller et al. Anchoring ethinylestradiol induced gene expression changes with testicular morphology and reproductive function in the medaka
Alcaraz et al. Development of a comprehensive toxicity pathway model for 17α-ethinylestradiol in early life stage fathead minnows (Pimephales promelas)
Mustapha et al. Comparative transcriptome analysis of the differentiating gonads in Scatophagus argus
Cereser et al. An evaluation of thiram toxicity on cultured human skin fibroblasts
Guo et al. Freshwater crustacean exposed to active pharmaceutical ingredients: ecotoxicological effects and mechanisms
Waller et al. Targeted metabolomics characterizes metabolite occurrence and variability in stable freshwater mussel populations
JP2007501617A (ja) 初代ラット肝細胞毒性モデリング
Xie et al. Integrated transcriptomics and metabolomics reveal the toxic mechanisms of mercury exposure to an endangered species Tachypleus tridentatus
Meador et al. Exposure of juvenile Chinook salmon to effluent from a large urban wastewater treatment plant. Part 2. Metabolomic profiling
Chen et al. Effects of whole life-cycle exposure to carbaryl on reproduction of female marine medaka (Oryzias melastigma) and their offspring
WO2003065993A2 (en) Primary rat hepatocyte toxicity modeling

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060124

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081216

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090519